Flupentixol

Evidence Level: L5

Predicted Indications: 9

Flupentixol

Pharmacist Assessment Report

Flupentixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Flupentixol is a thioxanthene antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently no clinical trials and no publications supporting this direction; the prediction is computational only.

Quick Overview

Item	Content
Original Indication	Schizophrenia (the Canadian licence records contain no approved indication text)
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	0.9999
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Flupentixol is known as a thioxanthene antipsychotic. Pharmacology records show it binds the dopamine D1, D2, D3 and D5 receptors, which underlies its use in schizophrenia.

No plausible pathway linking dopamine receptor antagonism to inherited retinal dystrophy is documented. The very high TxGNN score (0.9999) reflects a TxGNN model (deep learning) prediction only, and it should not be read as evidence of efficacy. Retinal dystrophies are typically genetic degenerative conditions, and there is no data suggesting an antipsychotic would alter their course.

Eight other predictions were also generated, including Charcot-Marie-Tooth disease type 1G, a congenital disorder of glycosylation, polymicrogyria, hydranencephaly, several forms of myopia, and atypical glycine encephalopathy. All are at the same L5, Hold level. The myopia predictions have only a speculative link through retinal dopamine signalling in eye growth, and a dopamine antagonist might act in the opposite direction to dopamine’s proposed protective effect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02156016	FLUANXOL 3MG - TAB	Tablet	Not stated in the licence data
02156008	FLUANXOL 0.5MG - TAB	Tablet	Not stated in the licence data

Safety Considerations

Drug Interactions: The interaction search completed, but it returned only pharmacological target-binding records, not drug-drug interactions. Flupentixol binds the dopamine D1, D2, D3 and D5 receptors.
Other Pharmacology Note: Drug repurposing screens have identified anti-SARS-CoV-2 activity for flupentixol, likely through phospholipidosis from disruption of lipid homeostasis. This is a property shared with other cationic amphiphilic drugs.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN model (deep learning) score. There are no clinical trials, no publications and no established mechanistic link to retinal dystrophy, so the evidence level is L5.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data
Preclinical or mechanistic evidence connecting dopamine receptor pharmacology to retinal dystrophy
A literature and trial search specific to the predicted indication
Assessment of route compatibility and the risk-benefit balance for the target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.